Poly(ADP-Ribose) Polymerase Inhibition as a Promising Approach for Hepatocellular Carcinoma Therapy

Area of Science:

• Oncology
• Hepatology
• Molecular Biology

Background:

• Primary liver cancer, predominantly hepatocellular carcinoma (HCC), is a leading cause of cancer death globally.
• Viral infections (HBV, HCV) are major causes of HCC, with limited treatment options for advanced stages.
• Radiotherapy is not a primary treatment for HCC, but radiosensitizing drugs could enhance its efficacy.

Purpose of the Study:

• To review the role of Poly(ADP-ribose) polymerase 1 (PARP1) in DNA damage repair within HCC.
• To explore the potential of PARP inhibitors and decoys as therapeutic strategies for HCC.
• To specifically consider the application in Hepatitis B virus (HBV)-related HCC.

Main Methods:

• Literature review focusing on DNA repair pathways in HCC.
• Analysis of PARP1's involvement in DNA damage response mechanisms.
• Examination of preclinical and clinical data on PARP inhibitors and decoys for HCC treatment.

Main Results:

• PARP1 plays a significant role in DNA repair pathways relevant to HCC.
• Inhibiting or decooying PARP1 shows potential to sensitize HCC cells to radiotherapy.
• This approach may offer a novel therapeutic avenue, particularly for HBV-associated HCC.

Conclusions:

• PARP1 modulation presents a promising strategy to improve radiotherapy outcomes in HCC.
• PARP inhibitors and decoys warrant further investigation as treatments for HCC.
• Targeting DNA repair mechanisms could overcome resistance and improve survival in HCC patients.